Ribavirin News and Research

RSS

Ribavirin, also known as Copegus, Rebetol, Virazole, or a component of Rebetron, is a type of antiviral medicine called a nucleoside analogue. This medicine blocks the ability of the hepatitis C virus (HCV) to make more copies of itself. Ribavirin is not active against HIV. Ribavirin is used in combination with interferon alfa-2a or -2b or peginterferon alfa-2a or -2b to treat HIV infected patients who are also infected with HCV.

Novel targets to inhibit SARS-CoV-2 variants

A new study identified additional targets on SARS-CoV-2 proteins to prevent the emergence of new SARS-CoV-2 variants of concern.

16 Mar 2022

Trial of early antiviral therapy for COVID-19 shows no significant benefit

A new preprint research paper examines the efficacy of using three antivirals in various combinations in early infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

17 Feb 2022

Study explains why Omicron infections are less likely to cause severe disease

A new study by researchers from the University of Kent and the Goethe University Frankfurt shows that the SARS-CoV-2 Omicron variant is less effective than Delta at blocking a cellular defense mechanism against viruses, the so-called “interferon response”.

24 Jan 2022

Study identifies current mechanism of action behind reduced severity of Omicron variant COVID-19 infection

New research shows evidence that the Omicron variant is less severe compared to the Delta variant.

6 Jan 2022

Screening FDA-approved compounds shown to possess antiviral or antimicrobial activity for SARS-CoV-2 inhibition

Researchers have screened several compounds that could show the ability to inhibit SARS-CoV-2.

10 Dec 2021

A survey on computational methods in discovering protein inhibitors of SARS-CoV-2

Researchers review diverse computational methods for drug/inhibitor design and enzymes as potential targets for inhibitors to treat coronaviruses diseases.

12 Oct 2021

Potential covalent SARS-CoV-2 spike protein inhibitors

There remains a significant need for new and effective drugs that can be used to treat COVID-19.

23 Sep 2021

Flavonoid-based inhibitors targeting SARS-CoV 3CL protease for the treatment of SARS-CoV-2 infection

A new study has explored a series of potential flavonoid inhibitors targeting 3CL protease of SARS-CoV.

9 Aug 2021

Potential compounds targeting SARS-COV-2 main protease (in vivo)

Now, new research published in the journal Hippokratia focuses on assisting the ongoing COVID-19 therapeutic research by developing a new method to identify active compounds that have the potential to fight against COVID-19 infection.

15 Jul 2021

Researchers review the origins of SARS-CoV-2 and present treatment methods

A million more questions arise for every answer we have against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Where did it come from? And will it ever go away? A recent article published in Frontiers in Cellular and Infection Microbiology reviews what scientists currently know about the origin, SARS-CoV-2 structure, and potential treatments against this new virus.

23 Jun 2021

SARS-CoV-2 NSP14 induces potent inflammation via NF-κB pathways, finds study

SARS-CoV-2 has a single-stranded RNA genome encoding both structural and non-structural proteins. Of these, the latter is known to play a variety of roles in viral replication and the assembly of new viral particles, as well as in suppressing cellular immune responses. A new study reports the activity of one such protein, the non-structural protein 14 (NSP14), which activates the inflammatory mediator NF-κB to trigger intense inflammation.

31 May 2021

Could graphene oxide nanosheets be an effective SARS-CoV-2 antiviral in PPE?

A new study has been published in Small, which has combined in silico and in vitro analysis to examine if graphene oxide (GO) sheets have an inhibitory effect against SARS‐CoV‐2 surface proteins.

20 May 2021

Natural products a rich source for novel antiviral compounds

In a recent review in the journal Viruses, researchers look at natural products that can be identified as potential alternative antiviral agents. The reviewers discussed the antiviral activities of several natural products towards DNA and RNA viruses with an analytical approach. The researchers detailed the cellular/viral targets of the active molecules and their impact on the infection and viral replication cycle.

10 May 2021